Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Mindfulness to Enhance Quality of Life and Support Advance Care Planning (MEANING)

10. August 2020 aktualisiert von: Shelley Johns, Indiana University

Mindfulness to Enhance Quality of Life and Support Advance Care Planning (MEANING): A Randomized Controlled Pilot Trial for Adults With Metastatic Cancer and Their Family Caregivers

The MEANING trial is a randomized controlled mixed methods pilot designed to compare a novel mindfulness meditation-based intervention (MEANING) to usual care for adults with advanced-stage solid malignancies and their family caregivers.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Mindfulness meditation practices have reduced emotional distress, avoidant coping, and improved spiritual well-being in adult cancer patients. These beneficial effects may occur through present-moment acceptance of unpleasant thoughts, feelings, and circumstances and adaptive coping through self-awareness, self-regulation, and self-transcendence. Most mindfulness trials in cancer have focused on early-stage survivors; however, preliminary evidence suggests that mindfulness may help reduce distress in patients with advanced cancer and their family caregivers (FCGs).

Sixty patients with an advanced-stage solid malignancy and their FCGs (60 dyads) will be randomized in equal numbers to receive either the 6-week mindfulness intervention or usual care. Both groups will receive standard cancer care throughout the study period. Dyads randomized to the mindfulness arm will learn mindfulness meditation practices (e.g., body scan, sitting meditation) and mindful communication practices to enhance quality of life, support advance care planning engagement, and improve a variety of secondary outcomes.

The study will use a mixed methods 2-arm randomized design to examine the effects of the mindfulness intervention compared to usual care and seek to explain trial results using insights gleaned from post-intervention qualitative interviews.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

108

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Vereinigte Staaten
    • Indiana
      • Indianapolis, Indiana, Vereinigte Staaten, 46202
        • Indiana University

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria-Patients

  • Patient is at least 18 years of age.
  • Patient is at least 3 weeks post-diagnosis of an incurable (locally advanced or metastatic) solid malignancy.
  • Patient's attending medical oncologist would not be surprised if the patient died in the next 12 months.
  • Patient has not completed a POST form.
  • Patient scores ≥ 7 on the Mini-Mental Adjustment to Cancer cognitive avoidance subscale.
  • Patient is willing and able to consent and travel to the class location for 6 weekly 2-hour sessions.
  • Patient has a family member or close friend eligible and interested in participating in the study.
  • Patient has adequate English fluency for completion of data collection

Inclusion Criteria-Family Care Givers (FCG)

  • FCG is at least 18 years of age.
  • FCG has been invited to participate in the trial with a patient who meets eligibility criteria above.
  • FCG is willing and able to consent and travel to the class location for 6 weekly 2-hour sessions.
  • FCG has adequate English fluency for completion of data collection

Exclusion Criteria-Patients

  • Patient reports a score of > 2 on the Activities and Function item from the Patient Generated Subjective Global Assessment91 (PG-SGA; the patient-reported version of the Eastern Cooperative Oncology Group score).
  • Patient makes 3 or more errors on a validated 6-item cognitive screener or exhibits significant psychiatric or cognitive impairment (e.g., dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation.
  • Currently receiving hospice care (patients who enroll in hospice during the trial will have the option of continuing trial participation).

Exclusion Criteria-FCGs

• FCG exhibits significant psychiatric or cognitive impairment (e.g., dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Unterstützende Pflege
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Kein Eingriff: Usual Care
Participants assigned to Usual Care will continue to receive standard care from their oncology team, including access to supportive care from oncology social workers. At the end of the study, usual care dyads will receive a packet of informational materials on mindfulness meditation, receive a CD with 5 mindfulness meditation practices, and meet with the study interventionist for guidance on how to use the materials and mindfulness recordings to their advantage in coping with cancer-related challenges.
Aktiver Komparator: Mindfulness
The Mindfulness intervention will consist of six 2-hour sessions that will include guided mindfulness practices, didactics, and group discussion. The course curriculum is modeled on the Mindfulness-Based Stress Reduction program which involves intensive experiential training of participants in secular mindfulness meditation practices (i.e., body scan, sitting meditation, gentle hatha yoga with chair adaptations, compassion meditation), with an emphasis on embodying interpersonal mindfulness in dialogue.
Verhalten: Mindfulness
The Mindfulness intervention sessions are designed to cultivate present-moment awareness in everyday life to facilitate adaptive and non-reactive relating to thoughts, feelings, and bodily sensations. Participants will be provided with 10-20 minute audio recordings of each of 5 mindfulness practices covered in class, recorded in the facilitator's voice. Participants will be encouraged to practice mindfulness at home 10-20 minutes per day, 6 days per week. Participants will be provided with weekly diaries on which to record type and amount of home practice of mindfulness skills.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from baseline in quality of life (QoL) for Patients
Zeitfenster: Baseline, 6 weeks, and 10 weeks
QoL for patients will be assessed with the McGill Quality of Life Inventory.
Baseline, 6 weeks, and 10 weeks
Change from baseline in quality of life (QoL) for Family Caregivers
Zeitfenster: Baseline, 6 weeks, and 10 weeks
QoL for family caregivers will be assessed with the Caregiver Quality of Life - Cancer scale (CQoLC).
Baseline, 6 weeks, and 10 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from baseline in advance care planning (ACP) stage of change
Zeitfenster: Baseline, 6 weeks, and 10 weeks
ACP stage of change will be assessed by a measure modified from Fried et. al assessing stage of change for 3 advance care planning behaviors (completing a living will, medical power of attorney form, or POLST form; patient only measure).
Baseline, 6 weeks, and 10 weeks
Change from baseline in advance care planning (ACP) engagement
Zeitfenster: Baseline, 6 weeks, and 10 weeks
ACP engagement (self-efficacy, readiness) will be measured using 2 subscales of the Advance Care Planning Engagement Survey (patient only measure).
Baseline, 6 weeks, and 10 weeks
Change from baseline in caregiver burden
Zeitfenster: Baseline, 6 weeks, and 10 weeks
Caregiver burden will be measured using the Zarit Burden Interview (family caregiver measure only)
Baseline, 6 weeks, and 10 weeks
Change from baseline in avoidant coping
Zeitfenster: Baseline, 6 weeks, and 10 weeks
Avoidant coping will be assessed using the Mini-MAC Cognitive Avoidance subscale
Baseline, 6 weeks, and 10 weeks
Change from baseline in avoidant coping
Zeitfenster: Baseline, 6 weeks, and 10 weeks
Avoidant coping will be assessed using the Brief COPE Self-Distraction, Denial, and Behavioral Disengagement subscales
Baseline, 6 weeks, and 10 weeks
Change from baseline in depressive symptoms
Zeitfenster: Baseline, 6 weeks, and 10 weeks
Depressive symptoms will be assessed using the PHQ-8
Baseline, 6 weeks, and 10 weeks
Change from baseline in anxiety
Zeitfenster: Baseline, 6 weeks, and 10 weeks
Anxiety will be assessed using the GAD-7
Baseline, 6 weeks, and 10 weeks
Change from baseline in spiritual well-being
Zeitfenster: Baseline, 6 weeks, and 10 weeks
Spiritual well-being will be measured using the FACIT-SP.
Baseline, 6 weeks, and 10 weeks
Change from baseline in sleep disturbance
Zeitfenster: Baseline, 6 weeks, and 10 weeks
Sleep disturbance will be assessed using the PROMIS Sleep Disturbance.
Baseline, 6 weeks, and 10 weeks
Change from baseline in family communication
Zeitfenster: Baseline, 6 weeks, and 10 weeks
Family communication will be assessed using the Social Constraint Scale
Baseline, 6 weeks, and 10 weeks
Change from baseline in interpersonal closeness
Zeitfenster: Baseline, 6 weeks, and 10 weeks
Interpersonal closeness will be assessed using the Perceived Interpersonal Closeness Scale.
Baseline, 6 weeks, and 10 weeks
Change from baseline in acceptance of illness
Zeitfenster: Baseline, 6 weeks, and 10 weeks
Acceptance of illness will be assessed using the PEACE Scale.
Baseline, 6 weeks, and 10 weeks
Change from baseline in mindfulness
Zeitfenster: Baseline, 6 weeks, and 10 weeks
Mindfulness will be assessed using the FFMQ-SF Non-reactivity to Internal Experience and Acting with Awareness subscales.
Baseline, 6 weeks, and 10 weeks
Distress Thermometer
Zeitfenster: Baseline, 6 weeks, and 10 weeks
Distress will be assessed using the Distress Thermometer.
Baseline, 6 weeks, and 10 weeks
Intervention satisfaction and helpfulness
Zeitfenster: 6 weeks
Satisfaction and helpfulness with the Mindfulness intervention will be assessed using single-item investigator-created 7- and 10-point Likert scales, respectively (Mindfulness group only).
6 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Indiana University

Ermittler

  • Hauptermittler: Shelley A Johns, PsyD, Indiana University School of Medicine

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

9. Mai 2017

Primärer Abschluss (Tatsächlich)

11. Dezember 2017

Studienabschluss (Tatsächlich)

11. Dezember 2017

Studienanmeldedaten

Zuerst eingereicht

16. August 2017

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. August 2017

Zuerst gepostet (Tatsächlich)

22. August 2017

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. August 2020

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. August 2020

Zuletzt verifiziert

1. August 2020

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 1702223546

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Lebensqualität

Klinische Studien zur Mindfulness

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Israel

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren